Sumitomo Pharma Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.4M | +1.24% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.6M | +2.17% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.2M | -1.72% | |
|
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund
|
654.0K | +55.71% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
615.4K | +5.07% | |
|
OBERWEIS FUNDS-Oberweis International Opportunities Fund
|
517.4K | -2.60% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
41.1K | +52.50% |
Dividend History
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2023 | ¥7 | -75.0% |
| 2022 | ¥28 | 0.0% |
| 2021 | ¥28 | 0.0% |
| 2020 | ¥28 | -20.0% |
| 2019 | ¥35 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥560,035M | ¥555,544M | ¥314,558M | ¥398,832M |
| Gross Profit | ¥402,908M | ¥376,625M | ¥187,981M | ¥245,395M |
| Operating Income | ¥60,234M | -¥76,979M | -¥354,836M | ¥29,709M |
| Pretax Income | ¥86,011M | -¥44,761M | -¥318,837M | ¥31,111M |
| Net Income | ¥56,413M | -¥74,512M | -¥314,969M | ¥23,634M |
| EPS | ¥141.99 | -¥187.55 | -¥792.79 | ¥59.49 |
| Operating Margin | 10.76% | -13.86% | -112.80% | 7.45% |
| Balance Sheet | ||||
| Total Assets | ¥1,308,007M | ¥1,134,742M | ¥907,506M | ¥742,604M |
| Total Equity | ¥607,888M | ¥406,749M | ¥156,063M | ¥169,479M |
| Total Liabilities | ¥700,119M | ¥727,993M | ¥751,443M | ¥573,125M |
| Cash | ¥202,984M | ¥143,478M | ¥29,047M | ¥23,116M |
| Interest-bearing Debt | ¥269,048M | ¥334,716M | ¥418,884M | ¥305,422M |
| Equity Ratio | 46.47% | 35.85% | 17.20% | 22.82% |
| D/E Ratio | 0.44 | 0.82 | 2.68 | 1.80 |
| Cash Flow | ||||
| Operating CF | ¥31,239M | ¥11,937M | -¥241,893M | ¥16,500M |
| Investing CF | -¥18,278M | ¥52,419M | ¥33,036M | ¥99,754M |
| Financing CF | -¥21,426M | -¥146,817M | ¥77,851M | -¥108,836M |
| Free CF | ¥17,745M | -¥805M | -¥257,623M | ¥3,470M |
| Efficiency | ||||
| ROE | 9.28% | -18.32% | -201.82% | 13.95% |
| ROA | 4.31% | -6.57% | -34.71% | 3.18% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4506
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,158
Rating Score: 2.71 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
